Dog,

IMO "coiled" is an acceptable description of CGNH's share price; investors like myself are waiting on the results of the head-to-head study. IMO -

• If the data supports CGNH's claim of equal or superior diagnostic results within minutes rather than hours, the share price is poised to "spring" upward (beyond the $1.40 high).

• If the head-to-head study fails to demonstrate equal or superior results the CGNH share price could fall to single digits.

• Should CGNH announce another delay in the conduct of the head-to-head study, investors (myself included) will begin to liquidate their holdings of CGNH shares.

IRB's typically meet to review study protocols in their institutions on a monthly basis and development companies typically have "all of their ducks in a row" prior to the IRB reviewing the study protocol. If CGNH has performed typically, the study should be primed to start in Q1; whether the results are known by the end of the quarter should depend primarily on the availability of subjects who meet study enrollment criteria.

Typically IRB approval is not a material event but given CGNH's history of public statements regards the head-to-head study IMO announcing IRB approval and enrollment of patients into the study is now a material event. But also given CGNH's history of keeping its shareholders in the dark and uninformed, IMO they will not issue a Press Release announcing these events.

Ante